Summary: In a small single-centre study of 67 overweight or obese adults with type 2 diabetes, adding a long-acting GLP-1 receptor agonist (dulaglutide or semaglutide) to metformin produced a significantly lower BMI than metformin alone at 6 and 12 months (P < .001 for the between-group and interaction effects). HbA1c and fasting plasma glucose improved over time in both arms (time effect P < .001), but no significant between-group glycaemic advantage was reported. Adverse-event rates did not differ between groups (P > .05).
PICO Summary
| Element | Detail |
|---|---|
| Population | 67 overweight or obese adults with type 2 diabetes seen July 2021 to June 2022; single centre, China. The report describes itself as a real-world study while also stating patients were randomly allocated. |
| Intervention | Metformin plus a long-acting GLP-1 receptor agonist (dulaglutide or semaglutide); n = 32. |
| Comparison | Metformin alone; n = 35. |
| Outcome | BMI: significant between-group effect (P < .05) and interaction effect (P < .001), with lower BMI in the intervention arm at 6 and 12 months (P < .001). HbA1c and fasting plasma glucose: significant within-group time effect in both arms (P < .001), with no significant between-group difference reported. Adverse reactions: no significant difference between groups (P > .05). Effect sizes, 95% confidence intervals, and absolute risk reduction or number needed to treat were not reported. |
Expert Commentary
This small study is best read as hypothesis-generating rather than confirmatory. The headline signal that survives scrutiny is a between-group reduction in BMI favouring the GLP-1 receptor agonist arm, which is consistent with the established weight effect of this drug class. The glycaemic claim is weaker than it first appears: although HbA1c and fasting plasma glucose fell over time, that time effect was seen in both arms and a significant between-group glycaemic advantage was not demonstrated, so any earlier framing of a clear HbA1c benefit over metformin alone overstates what was shown. The dominant limitation is statistical power. With only 67 participants split across two arms, the analysis is underpowered to detect between-group glycaemic differences, and the absence of reported effect sizes, confidence intervals, and absolute risk reduction makes the magnitude and precision of any benefit impossible to judge. The single-centre setting, the apparent lack of blinding, and the mixing of two different agents further limit generalisability, and the design is described inconsistently as both real-world and randomly allocated. Can I use this with my patients? Not on the strength of this study alone; for an overweight patient with type 2 diabetes seeking weight reduction the broader trial evidence for GLP-1 receptor agonists is the better basis for decisions. Larger, adequately powered, transparently reported trials with prespecified glycaemic endpoints are needed before this real-world signal changes practice.
References
Yang W, Zhou X, Miao Y, Wang L, Zhao Y, Ke T, Ban L. Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance. Medicine (Baltimore). 2024;103(32):e38879. doi:10.1097/MD.0000000000038879
